title: Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
abstract: BACKGROUND
  Therapy for HCV-infected patients after orthotopic liver transplantation (OLT) is based on interferon (IFN) as the gold standard, but sustained virologic response (SVR) and safety profiles of the IFN-based therapies are very unsatisfactory. The aim of this continuing analysis is evaluation of the impact of an IFN-free sofosbuvir (SOF)-based therapy in HCV-infected liver transplant recipients.
  
  
  METHODS
  Post-OLT patients with a proven recurrence of HCV were treated with SOF and ribavirin (RBV) for 24 weeks (n=10). Laboratory parameters and FibroScan® are continuously evaluated at weeks 0, 12, 24, and 36. A retrospectively analyzed HCV patient cohort who received antiviral therapy with pegylated INF and RBV± telaprevir (TLV) were used as a control group.
  
  
  RESULTS
  All patients who finished their treatment with SOF/RBV at least 12 weeks ago showed an SVR. The SOF-based therapy showed a significantly higher rate of rapid virologic response (RVR) and sustained virologic response (SVR) compared to the IFN-based therapies (RVR: p=0.007; SVR: p=0.009). According to temporary data on FibroScan® analysis, regression of fibrosis was observed in 8 patients treated with SOF/RBV. No premature termination of SOF became necessary.
  
  
  CONCLUSIONS
  In this small group of patients, the preliminary results indicate that a regression of fibrosis is achievable within 24 weeks of therapy with SOF after OLT. SOF seems to be effective and safe in the treatment of OLT patients infected with HCV and will likely improve patient and transplant survival.
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Leon Louis
authors.initials: LL
authors.lastname: Seifert
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Elena
authors.initials: E
authors.lastname: Vorona
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Caroline
authors.initials: C
authors.lastname: Bester
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Stahl
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Hüsing
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Beckebaum
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Iyad
authors.initials: I
authors.lastname: Kabar
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Hauke
authors.initials: H
authors.lastname: Heinzow
authors.affiliation: Department of Transplantation Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Hartmut H-J
authors.initials: HH
authors.lastname: Schmidt
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006085:Graft Survival; D006526:Hepatitis C / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069474:Sofosbuvir